George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This is an updated Exscientia presentation that's worth a read to any FIPP shareholders:
https://s28.q4cdn.com/460399462/files/doc_presentations/2022/06/Exscientia-IR-Presentation_June-2022.pdf
Page 10 is particularly impressive. 70% reduction in discovery time 80% better capital efficiency and 10x productivity designing optimal drug candidates.
The last reported NAV for FIPP was 84.7p so that puts it on a discount to NAV of 28% at current prices. The market perceives this NAV has shrunk but FIPP has a consistent track record of achieving NAV growth so we'll see. Lots (17) of exciting portfolio companies which are beavering away. We are due a trading update, and then the full year results will arrive in 3 months too.
GLA
I disagree - I’m delighted that FIPP are holding a good chunk of Exscientia - the prospects are very positive:
https://investors.exscientia.ai/press-releases/press-release-details/2022/Exscientia-Business-Update-for-First-Quarter-2022/default.aspx
So many of Frontiers investments seem to be spot on for todays market place. From software that increases efficiency for logistics companies reducing fuel. To covid vaccines and robots to reduce farm labour in short supply. Plusiv - which reduces electricity consumption. A fantastic range of products maturing for todays world
Each robot has x4 arms however. So x16kg/hour working 24hrs a day and with only the best fruit picked. The robot also remembers where and when to return to almost ready fruit. The quality of the berries is also better than picked by hand as the robot is more delicate and precise
The Guardian has picked up on the progress of Fipps 22.2% owned Fieldwork Robotics.
https://www.theguardian.com/business/2022/jun/01/uk-raspberry-picking-robot-soft-fruit
It adds a bit more detail to what was mentioned in Fipps recent newsletter. I must admit I was slightly underwhelmed that it could pick 1kg of raspberries in one hour. However compared to a rate of 1 berry per minute 3 years ago, that’s quite an advance. Also pleasing to read they expect to improve to 4kg an hour which would be 25000 berries a day. Still very early days in commerciality but could be a very big market in a few years.
There was no mention of Pulsiv in the newsletter. The board has been strengthened with new CEO, CSO and CFO appointed in last year. The usually understated Neil Crabb has often flagged up hopes that Pulsiv will be a major green energy company. Hopefully we will hear news of a major commercial agreement for them soon.
roughly NAV (given weakness of EXAI sp)...but excellent management in world class space; exciting book and exposure to EXAI rally
Hi Acuere
Stomach churning stuff to lose all the profit on a stock. It's happening on a lot of stocks across the board at the moment and it's a tough investment environment.
I'm not clear why they only sold 25% as Exai looked overvalued in the $20s. I did read that there was a 6 month lock in or something for pre IPO investors and maybe Fipp only got permission to sell 25% earlier than the lock in period?
If there were no restrictions then it could have sold 50-75% or just retained a small stake. It's an early stage investor so doesn't make sense holding on to such big stakes.
Exai is also at early clinical stage with its drug and partnership programs and will at some stage require more funding hopefully not diluting us greatly.
Yes looking forward to news regarding progress on the investments.
The loss of 1/3 of the share price in a month looks a bit harsh here.
Aside general market sentiment, the main reason for the fall can be attributed to the drop in the SP of Exscientia. Fipp sold 25% of their holding earlier this year at about $20 a share, since when the price has slipped as low as $6.58 today.
However looking at Exscientia, with a market cap of $900m, it looks oversold to me. At end of December they had cash/cash equivalents of $758m and have since announced a collaboration with Sanofi with $100m upfront cash payment and potentially worth $5.2bn.
I can see Exai bouncing sharply when sentiment changes and with some of Fipps other investment projects reaching important inflection points, this looks too cheap at 70p.
Just appeared in IC. Should see strong gains Monday. Great write up. Should reach previous highs.
Looking forward to Simon T's latest review on FIPP.
Link to Simon Thompson update
https://www.investorschronicle.co.uk/ideas/2022/01/14/a-smart-technology-play/
Tipped again by Simon Thompson on Friday evening...
As confirmed today, FIPp are still holding ex but have been selling down to monetise the position. Bunch of other companies now at inflection points.
Big deal secured by Exscientia. $100m upfront and potentially $5.3bn revenue. If Fipp still holding I would expect to see an RNS about it.
“Sanofi SA and Exscientia PLC are to partner on drug development in oncology and immunology in a deal that could see the latter receive up to $5.3 billion, the two pharmaceutical companies said Friday.
Paris-listed Sanofi and U.K.-based Exscientia will collaborate to identify and select target projects, using Exscientia's artificial-intelligence-driven personalized medicine platform.
Under the research, collaboration and licensing agreement, the two companies will develop up to 15 novel small-molecule candidates in oncology and immunology, they said in a joint release.
Sanofi will pay Exscientia an upfront cash payment of $100 million, while future payments could reach some $5.2 billion, relating to commercial, clinical and regulatory milestones, the companies said.
If Sanofi commercializes a therapeutic treatment from the collaboration, Exscientia will also be eligible to receive tiered royalties on product sales ranging from a rate of high single digits to mid-teens, and an option for clinical co-investment to increase the royalty rate up to 21% on net sales of cofunded products, the companies said.“
TVG mentioned here:
https://www.theguardian.com/business/2021/dec/11/as-covid-mutates-the-vaccine-makers-are-adapting-too
Nicely timed announcement about The Vaccine Groups progress with a new vaccine. I have sorry for the panicked investors selling at below a £1 last Friday though.
Jeremy Salt, Chief Executive of The Vaccine Group, said: "These very strong trial results show that a COVID-19 vaccine based on our novel herpesvirus platform could prove to be extremely effective in mitigating the long-term impact of the disease. We are clearly excited about the potential for the vaccine."
Excellent set of figures.
Worth noting that within that 30 Jun portfolio valuation of £31.98m, Exscientia was valued at £13.3m. At the IPO price it was valued at £25m.
Lots of forward comments to like about the core companies. I’ll just highlight one for now. Pulsiv looks like it could provide next catalyst for SP rise.
“(Pulsiv)….. will become a major green technology business.
Its unique technology improves the efficiency of electricity conversion meaning devices waste much less energy than conventional techniques. If widely adopted, it means electricity grids can generate less electricity to meet the demand from devices and appliances. It can be used in virtually all mains-powered devices and has a host of other applications.. . . . and is now in advanced discussions with a number of major companies about integrating it into their devices.”
Another encouraging article...FIPP contains some excellent startup companies eg Exscientia which has been valued at $2.6 by
FIPP has £25 million of that but only on its books at £6.3 ! Nice.
Worth a read
https://wp-frontier-2020.s3.eu-west-2.amazonaws.com/media/2021/10/15080716/Frontier-News-October-2021.pdf
Anybody have any idea what is happening with this share, dipping then coming back strongly?
I spent last weekend researching shares and this was my number one pick, which I invested in on Monday. It rapidly rose on Monday morning - which appeared to be due to my investment. I couldn't believe that my buys (total £10k) had such an effect on a relatively large company, but I was watching it on L2 and I could see the effect. There must be a very small free float of shares.
Then it all went pear-shaped for no apparent reason. Then today it went back into profit. Crazy.
Sorry that is the last paragraph of Simon thompsons article should be emailed at 7am to 30k odd database, hope the mm's don't jack it up before the opening
I see scope for Frontier IP's share price to rally back to this year's 114p highs, and beyond, given the operational progress made by investee companies and the huge unrealised gains on the Exscentia stake. Buy.
ST's upsate on FIPP was published online about 4 hours ago.
https://www.investorschronicle.co.uk/ideas/2021/03/05/exploit-two-small-cap-pricing-anomalies/
for that ST article? Maybe you need to be logged in...